Attachment: Extract from Clinical Evaluation Report ...

Combination therapy with endothelin receptor antagonists, phosphodiesterase type-5 inhibitors and prostacyclin analogues did not affect survival but improved multiple outcome measures such as 6MWD, functional class and quality of life.(16) In conclusion, PH treatment remains mainly supportive in ILDs with the exception of systemic sclerosis ... ................
................